# Tesamorelin (Egrifta)

**Last Updated:** December 4, 2025
**OCEBM Evidence Level:** 1-2 (Phase III RCT, FDA Approved)
**Risk Profile:** LOW (when monitored)
**FDA Status:** APPROVED (2010)

---

## What Is This?

Tesamorelin is an **FDA-approved GH secretagogue** — meaning it tells your pituitary to release growth hormone naturally. It's the only GH-boosting peptide with Phase III data and FDA approval (for HIV lipodystrophy). Clinical trials show **15-20% visceral fat reduction** — the dangerous belly fat around organs. Off-label, it's popular for body recomposition and anti-aging. Key advantage over synthetic GH: it preserves your body's natural pulsatile GH release pattern. Downsides: expensive (~$1,000-1,500/month), effects reverse when you stop, and requires monitoring IGF-1 levels.

---

## Categories

`GH Axis` · `Metabolic / Fat Loss`

---

## Glossary

| Term | Meaning |
|------|---------|
| OCEBM | Oxford Centre for Evidence-Based Medicine — rates evidence quality |
| GHRH | Growth Hormone Releasing Hormone — what tesamorelin mimics |
| GH | Growth Hormone — released by pituitary, declines with age |
| IGF-1 | Insulin-like Growth Factor 1 — downstream marker of GH action |
| VAT | Visceral Adipose Tissue — dangerous fat around organs |
| Lipodystrophy | Abnormal fat distribution (the FDA-approved indication) |
| Pulsatile | Released in pulses rather than continuously |
| Secretagogue | Substance that causes release of another substance |
| ULN | Upper Limit of Normal — reference range ceiling |

---

## Key Specifications

| Property | Value |
|----------|-------|
| Brand Name | Egrifta SV |
| Type | 44-amino acid GHRH analog |
| Half-life | 26-38 minutes |
| Approved Dose | 2mg daily SC |
| Approved Indication | HIV lipodystrophy |
| Cost | ~$1,000-1,500/month (US retail) |

---

## Clinical Evidence

The evidence base for tesamorelin stands alone among GH secretagogues. Two Phase III trials enrolled 806 patients with HIV-associated lipodystrophy, establishing not just statistical significance but clinically meaningful outcomes. At 26 weeks, tesamorelin-treated patients demonstrated visceral adipose tissue reduction of 15-19.6% compared to roughly 2% in placebo groups. More importantly, 69% of tesamorelin users achieved the responder threshold (>8% VAT reduction) versus only 33% on placebo — a clinically relevant distinction when considering the financial and monitoring burden of treatment.

The 2024 update from Theratechnologies refined these findings further: visceral fat decreased by an average of 25 cm² in treated patients while increasing by 14 cm² in controls. This isn't merely aesthetic — visceral adipose tissue drives metabolic dysfunction, inflammatory signaling, and cardiovascular risk in ways subcutaneous fat does not.

Beyond fat reduction, metabolic parameters improved. Triglycerides and total cholesterol decreased, though fasting glucose showed variable responses requiring monitoring. The metabolic improvements appear mechanistically linked to the visceral fat reduction itself rather than direct insulin-sensitizing effects, underscoring the importance of sustained treatment for metabolic benefits.

Critically, all these effects reverse upon discontinuation. This isn't a criticism of the compound — it reflects the underlying mechanism. Tesamorelin stimulates GH release; when you stop stimulating it, GH returns to baseline, and with it, the metabolic environment that allowed visceral fat accumulation in the first place. This pharmacological reality makes tesamorelin a chronic intervention, not a short-term fix.

---

## Mechanism of Action

Tesamorelin functions as a GHRH analog, binding to GHRH receptors in the anterior pituitary and triggering endogenous growth hormone release. This matters because it preserves the body's natural pulsatile secretion pattern — GH pulses 6-8 times daily, with the largest pulse occurring during deep sleep. This pulsatility maintains receptor sensitivity and downstream signaling integrity in ways that continuous GH exposure (as with synthetic GH injections) does not.

Once released, GH exerts lipolytic effects both directly and through IGF-1 production in the liver. The lipolysis preferentially targets visceral adipose tissue, which expresses higher densities of beta-adrenergic receptors responsive to GH-mediated signaling. Trunk fat and subcutaneous stores also decrease, but the visceral depot shows the most dramatic response.

The 26-38 minute half-life means tesamorelin itself clears rapidly, but the GH pulse it triggers persists for hours, with IGF-1 elevations lasting days. This creates a sustained metabolic signal from a brief peptide exposure — an elegant pharmacological profile that reduces injection-site complications and systemic peptide exposure while maintaining efficacy.

---

## Use Cases by Goal

Understanding who benefits from tesamorelin — and why — requires matching mechanism to physiology. The compound works best when GH signaling is deficient and visceral fat is elevated. It works least well when you're trying to push already-optimal GH levels higher or eliminate the last few pounds of subcutaneous fat.

### Visceral Fat Reduction (FDA-Approved)

The FDA approved tesamorelin for HIV-associated lipodystrophy, but the mechanism — GH-mediated visceral fat mobilization — operates independently of HIV status. What matters is the presence of pathological visceral fat accumulation. Users report noticeable belly fat reduction within 4-6 weeks, with the full effect manifesting by 12-16 weeks. One user described it as "visceral fat that wouldn't budge finally moved" — capturing the frustration of diet-resistant central adiposity that yields once GH signaling improves.

The standard protocol uses 2mg subcutaneously daily, timed in the evening to align with nocturnal GH pulses, though any consistent timing works. Effects require ongoing treatment; one user reported "waistline down 5.5 inches after 3 months" but noted maintenance required continued dosing.

### Body Recomposition / Anti-Aging

Body recomposition represents the most common off-label use. The rationale extends from the FDA indication: if GH stimulation reduces visceral fat while maintaining or increasing lean mass, the compound should improve body composition broadly. User experience supports this, with consistent reports of "weight may not change but body composition does" and "six months... midsection finally looks different."

The protocol remains 2mg daily, but duration matters more here. Minimum 8-12 weeks for initial effects, 16-20 weeks for stubborn visceral fat, and ongoing cycles for maintenance. All non-HIV indications are off-label extrapolations using the approved 2mg/day dose — an important medicolegal distinction.

### Anti-Aging / Longevity (Off-Label)

GH declines roughly 1-2% annually after age 30, contributing to age-related changes in body composition, tissue quality, and recovery capacity. Tesamorelin restores GH pulsatility toward more youthful patterns. Users report improved sleep quality, faster workout recovery, and enhanced skin appearance — effects consistent with GH's broad tissue-remodeling actions.

The anti-aging protocol uses either 2mg daily or a 5-days-on/2-days-off pattern to prevent receptor desensitization. This represents ongoing cycles rather than time-limited treatment, raising the importance of monitoring protocols discussed below.

### Cognitive Support (Exploratory)

IGF-1 exerts neurotrophic effects — supporting neuronal survival, synaptic plasticity, and neurogenesis. Studies in HIV-associated cognitive impairment showed cognitive benefits with tesamorelin, though whether this extends to non-HIV populations remains exploratory. The protocol would be 2mg daily ongoing, but this sits at evidence level 4-5 rather than the level 1-2 evidence supporting metabolic indications.

### TITAN Protocol Integration

The TITAN protocol recognizes that chronic GH secretagogue use may cause receptor desensitization, reducing efficacy over time. The solution: cycle between different secretagogues with different receptor targets. Tesamorelin, having the strongest evidence base, serves as Phase 1 (weeks 1-8) at 2mg evening dosing, followed by switching to Ipamorelin/CJC-1295 (weeks 9-16) before potentially cycling back. This maintains GH axis stimulation while preserving receptor sensitivity.

---

## Risk Assessment

Tesamorelin's risk profile sits at the favorable end of the GH-axis intervention spectrum — lower than synthetic GH, comparable to other GH secretagogues, but not zero.

The most common side effects are injection-site reactions and initial water retention, both typically resolving within the first few weeks. Joint pain (arthralgia), muscle pain (myalgia), and tingling (paresthesias) affect 5-10% of users. Carpal tunnel syndrome remains rare but represents the most concerning non-metabolic adverse effect, resolving with dose reduction or discontinuation.

The more serious risk concerns revolve around IGF-1 elevation. While tesamorelin stimulates physiological GH pulses rather than creating supraphysiological continuous exposure, it does raise IGF-1 levels. Epidemiological data link chronically elevated IGF-1 to increased cancer risk, particularly colorectal, breast, and prostate cancers. No cancer signal emerged in the Phase III trials, but those trials lasted 26 weeks — insufficient to detect oncogenic risk that manifests over years.

Glucose metabolism deserves particular attention. GH creates insulin resistance as a counterregulatory mechanism. Most users tolerate this without issue, but those with prediabetes or diabetes risk worsening glycemic control. This makes fasting glucose, fasting insulin, and HbA1c monitoring non-negotiable.

The theoretical cancer risk — emphasized by tumor marker monitoring in the protocol below — reflects not a proven danger but a mechanistically plausible concern that responsible use must address. IGF-1 promotes cell survival and proliferation; if a nascent cancer exists, IGF-1 elevation could accelerate its growth. This makes baseline tumor marker assessment and ongoing surveillance a core element of safe use.

---

## Synergies and Stacking

Tesamorelin stacks well with compounds that complement rather than duplicate its mechanism. Stacking with other GH secretagogues (Ipamorelin, CJC-1295) makes sense only in the cycling context described in TITAN protocol — simultaneous use adds no benefit and increases desensitization risk.

More logical combinations include:

**Metabolic enhancers**: Metformin or berberine mitigate GH-induced insulin resistance while providing their own longevity signals. This represents a synergistic rather than redundant combination.

**Mitochondrial support**: CoQ10, NAD+ precursors (NMN/NR), or MOTS-c address energy production and mitochondrial function, complementing the body composition changes tesamorelin drives.

**Senolytic cycles**: Since GH improves tissue quality and senolytics remove damaged cells, alternating tesamorelin with dasatinib+quercetin or fisetin creates a remodel-and-clear strategy.

The key principle: stack mechanisms, don't stack redundancies. If two compounds activate the same pathway, you're increasing side effects without proportional benefit.

---

## Timing and Administration

| Goal | Timing |
|------|--------|
| Fat loss | Evening (aligns with nocturnal GH) |
| General | Any consistent time |
| Optimization | 5 days on, 2 off (prevent desensitization) |

**IGF-1 Dose Adjustment:** If IGF-1 rises above ~1.3–1.5× age-adjusted ULN, reduce frequency to 1 mg/day or 2 mg 3–5×/week instead of daily.

### Administration

- Subcutaneous injection
- Abdomen preferred (rotate sites)
- Fasted or not—less critical than other GH secretagogues
- Store refrigerated; room temp for injection

---

## User Experience Timeline

| Timeframe | Reported Effects |
|-----------|------------------|
| Week 1-2 | Water retention, morning stiffness (resolves) |
| Week 4-6 | Visible fat reduction beginning |
| Week 8-12 | Significant visceral fat reduction |
| Month 3-6 | Full body composition benefits |
| Ongoing | Effects maintained with continued use |

**Critical:** Effects are NOT permanent—VAT returns after discontinuation.

---

## Side Effects

| Effect | Frequency |
|--------|-----------|
| Injection site reaction | Common |
| Water retention | Common (initial) |
| Arthralgia | 5-10% |
| Myalgia | 5-10% |
| Paresthesias | 5-10% |
| Carpal tunnel | Rare |

---

## Monitoring

| Test | Baseline | Ongoing | Rationale |
|------|----------|---------|-----------|
| IGF-1 (with Z-score) | Yes | Every 3 months | Track GH axis elevation |
| Fasting glucose | Yes | Every 3 months | GH-induced insulin resistance |
| Fasting insulin | Yes | Every 3 months | Calculate HOMA-IR |
| HbA1c | Yes | Every 3-6 months | Glucose dysregulation |
| PSA (men >40) | Yes | Every 6 months | Prostate surveillance |
| CEA | Yes | Every 6 months | Colorectal marker |
| CA-125 (women) | Yes | Every 6 months | Ovarian surveillance |
| ApoB, Lp(a) | Yes | Every 6-12 months | Cardiovascular risk |
| Cystatin C (if >50) | Yes | Every 6-12 months | Renal function (muscle-independent) |
| Lipids | Yes | Every 6 months | Standard metabolic |
| Body composition | Yes | Every 3-6 months | Track efficacy |

### Action Rules

**IGF-1 Rule (Z-Score Based):**
- Z-score > 2 (>2 standard deviations above mean): **Reduce dose by 50%** (e.g., 1mg/day or 2mg 3-5×/week)
- Z-score > 3: **Discontinue immediately**
- Target: Age-adjusted upper-normal range

**HbA1c Rule:**
- If HbA1c increases >0.5% from baseline OR exceeds 5.7%: **Initiate Metformin 500mg BID or Berberine**

**Tumor Marker Rule:**
- Any elevation in PSA, CEA, or CA-125: **Immediate cessation of ALL growth factors** (GH peptides, BPC-157, TB-500, GHK-Cu, Dihexa)

### Additional Red Flags Requiring Discontinuation

- New diabetes diagnosis
- Significant edema
- Any malignancy diagnosis

---

## Contraindications

- Active malignancy
- Pituitary surgery/tumor/radiation
- Pregnancy (Category X)
- Hypersensitivity to tesamorelin or mannitol

---

## vs Other GH Secretagogues

| Compound | FDA Status | Evidence | Advantage |
|----------|------------|----------|-----------|
| **Tesamorelin** | **Approved** | Phase III | Strongest evidence |
| Sermorelin | Discontinued | Phase II | - |
| Ipamorelin | Not approved | Phase I | Clean side effect profile |
| CJC-1295 | Not approved | Phase I | Synergistic with ghrelin mimetics |

**Tesamorelin Advantage:** Only GH secretagogue with Phase III data and FDA approval.

---

## Limitations

1. **Expensive** - $1,000-1,500/month retail
2. **Effects reverse** on discontinuation
3. **FDA indication** is HIV lipodystrophy only
4. **IGF-1 elevation** - theoretical cancer concern (no signal in trials)

---

## References

1. FDA Label NDA 022505 - Egrifta prescribing information
2. Falutz J, et al. Tesamorelin in HIV lipodystrophy. AIDS. 2007.
3. Stanley TL, et al. Tesamorelin for visceral fat. JAMA. 2014.
4. Theratechnologies Clinical Data Update. 2024.
